Real-World Data: Sponsors Should Ensure US FDA Access To Patient-Level Data Upon Submission

Informed consent from patients, or institutional review board waivers, are needed to allow bioresearch monitoring inspectors to review source records in a timely fashion without delaying a user fee date, FDA’s Cheryl Grandinetti tells an international good clinical practices workshop.